HER2-Positive Breast Cancer Global Market Report 2025

Global HER2 Positive Breast Cancer Market Report 2025

HER2-Positive Breast Cancer Global Market Report 2025 – By Treatment Type (Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types), By Route Of Administration (Parenteral, Oral, Other Route Of Administrations), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By End User (Hospitals, Homecare, Specialty Clinics, Other End User) – Market Size, Trends, And Global Forecast 2025-2034

Name: HER2-Positive Breast Cancer Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

HER2-Positive Breast Cancer Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

HER2-Positive Breast Cancer Global Market Report 2025

Proud Members Of

HER2-Positive Breast Cancer Market Definition

HER2-positive breast cancer refers to a type of breast cancer characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. This protein promotes the growth of cancer cells and is found in approximately 15-20% of breast cancers. HER2-positive breast cancer is generally more aggressive than HER2-negative forms but is treatable with targeted therapies that inhibit HER2 activity.

The main types of treatments for HER2-positive breast cancer are targeted therapy, chemotherapy, endocrine therapy, immunotherapy, and other treatment types. Targeted therapy is a cancer treatment that precisely attacks specific molecules, such as proteins or genes driving cancer growth, while sparing normal cells. These drugs are administered through various routes, including parenteral, oral, and other route of administrations. It is distributed through various channels such as hospital pharmacy, retail pharmacy, and online pharmacy and is used by various end users including hospitals, homecare, specialty clinics, and others.

HER2-Positive Breast Cancer Market Segmentation

The HER2-positive breast cancer market covered in this report is segmented –

1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types

2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User

Subsegments:

1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors

2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens

3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy

4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation, Cancer Vaccines

5) By Other Treatment Types: Radiation Therapy, Stem Cell Therapy, Hyperthermia Treatment, Gene Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)

HER2-Positive Breast Cancer Market Size and growth rate 2025 to 2029: Graph

HER2-Positive Breast Cancer Market Size 2025 And Growth Rate

The HER2-positive breast cancer market size has grown strongly in recent years. It will grow from $10.21 billion in 2024 to $10.96 billion in 2025 at a compound annual growth rate (CAGR) of 7.34%. The growth in the historic period can be attributed to increasing early detection and diagnosis, rising awareness of HER2-positive subtypes, growing investments in research and development, rising adoption of precision medicine, and growing focus on improving patient outcomes.

HER2-Positive Breast Cancer Market Growth Forecast

The HER2-positive breast cancer market size is expected to see strong growth in the next few years. It will grow to $14.41 billion in 2029 at a compound annual growth rate (CAGR) of 7.08%. The growth in the forecast period can be attributed to rising demand for liquid biopsy for non-invasive monitoring, rising adoption of combination treatments, growing focus on immunotherapies and novel drug formulations, increasing use of liquid biopsy techniques for non-invasive monitoring, and increasing number of specialized cancer treatment centers. Major trends in the forecast period include advancements in targeted therapies, novel formulations, innovations in immunotherapy approaches, the development of novel HER2-targeted therapies, and advancements in biomarkers for better patient stratification.

Book your 30 minutes free consultation with our research experts

HER2-Positive Breast Cancer Market Driver: Impact Of Immunotherapy Adoption On The HER2-Positive Breast Cancer Market

The strong adoption of immunotherapy is expected to propel the growth of the HER2-positive breast cancer market going forward. Immunotherapy refers to a medical treatment that enhances or modifies the immune system's natural ability to fight diseases, such as cancer, infections, and autoimmune disorders. The adoption of immunotherapy is attributed to its capability to enhance the immune system's ability to identify and eliminate cancer cells, providing better efficacy and fewer side effects than conventional treatments. Immunotherapy aids HER2-positive breast cancer by enhancing the body's immune system to recognize and attack HER2-overexpressing cancer cells, improving treatment outcomes and reducing the risk of recurrence. For instance, in July 2023, according to the American Association for Cancer Research, a US-based organization, in 2023, the FDA has approved 11 immune checkpoint inhibitors (ICIs), with at least one ICI authorized for the treatment of 20 different cancer types and for any solid tumor exhibiting specific molecular characteristics. Therefore, the strong adoption of immunotherapy is driving the growth of the HER2-positive breast cancer market.

Global HER2-Positive Breast Cancer Market Major Players

Major companies operating in the HER2-positive breast cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd., Incyte Corporation, BioNTech SE, MacroGenics Inc., CStone Pharmaceuticals Co. Ltd., Sorrento Therapeutics Inc., Syndax Pharmaceuticals Inc., Fate Therapeutics Inc., Ambrx Biopharma Inc.

Global HER2-Positive Breast Cancer Market Trend: Innovative Therapies In The HER2-Positive Breast Cancer Market

Major companies operating in the HER2-positive breast cancer market are focused on developing innovative therapies, such as her2-directed antibody-drug conjugates (ADCs), to streamline and enhance the treatment process for patients. HER2-directed antibody-drug conjugates (ADCs) are targeted cancer therapies that link an antibody specific to HER2 with a cytotoxic drug, delivering the drug directly to HER2-positive cancer cells for more effective treatment. For instance, in January 2024, AstraZeneca India Pharma Ltd., an India-based biopharmaceutical company, launched Trastuzumab deruxtecan. This innovative therapy was developed through a collaboration between AstraZeneca and Daiichi Sankyo. Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC), which delivers a cytotoxic drug directly to HER2-positive cancer cells, offering a more targeted and effective treatment for patients.

HER2-Positive Breast Cancer Market Merger And Acquisition: Roche Acquires Rights To Zion Pharma's ZN-A-1041 For Brain Metastases Treatment In HER2-Positive Breast Cancer

In May 2023, Roche Holding AG, a Switzerland-based pharmaceutical company, acquired rights to Zion’s lead program, ZN-A-1041, for an undisclosed amount. The acquisition aims to advance the development and commercialization of Zion Pharma's ZN-A-1041, a blood-brain-barrier-penetrant HER2 inhibitor, for treating brain metastases in HER2-positive breast cancer patients. Zion Pharma Limited, a China-based biotechnology company that specializes in providing drugs to treat HER2-positive breast cancer.

Regional Outlook For The Global HER2-Positive Breast Cancer Market

North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-positive breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the HER2-positive breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the HER2-Positive Breast Cancer Market?

The HER2-positive breast cancer market consists of sales of small molecule inhibitors, antibody-drug conjugates, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the HER2-Positive Breast Cancer Industry?

The HER2-positive breast cancer market research report is one of a series of new reports from The Business Research Company that provides HER2- positive breast cancer market statistics, including the HER2- positive breast cancer industry global market size, regional shares, competitors with the HER2- positive breast cancer market share, detailed HER2- positive breast cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the HER2- positive breast cancer industry. This HER2- positive breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

HER2-Positive Breast Cancer Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	10.96 billion
Revenue Forecast In 2034	$14.41 billion
Growth Rate	CAGR of 7.08% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The HER2-positive breast cancer market covered in this report is segmented – 1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types 2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User Subsegments: 1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors 2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens 3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy 4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation, Cancer Vaccines 5) By Other Treatment Types: Radiation Therapy, Stem Cell Therapy, Hyperthermia Treatment, Gene Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd., Incyte Corporation, BioNTech SE, MacroGenics Inc., CStone Pharmaceuticals Co. Ltd., Sorrento Therapeutics Inc., Syndax Pharmaceuticals Inc., Fate Therapeutics Inc., Ambrx Biopharma Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. HER2-Positive Breast Cancer Market Characteristics

3. HER2-Positive Breast Cancer Market Trends And Strategies

4. HER2-Positive Breast Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global HER2-Positive Breast Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global HER2-Positive Breast Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global HER2-Positive Breast Cancer Market Growth Rate Analysis

5.4. Global HER2-Positive Breast Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global HER2-Positive Breast Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global HER2-Positive Breast Cancer Total Addressable Market (TAM)

6. HER2-Positive Breast Cancer Market Segmentation

6.1. Global HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Targeted Therapy

Chemotherapy

Endocrine Therapy

Immunotherapy

Other Treatment Types

6.2. Global HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Parenteral

Oral

Other Route Of Administrations

6.3. Global HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

6.4. Global HER2-Positive Breast Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Homecare

Specialty Clinics

Other End User

6.5. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

HER2 Inhibitors (Trastuzumab, Pertuzumab)

Tyrosine Kinase Inhibitors (TKIs)

Antibody-Drug Conjugates (ADC)

Small Molecule Inhibitors

6.6. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Anthracycline-based Chemotherapy

Taxane-based Chemotherapy

Platinum-based Chemotherapy

Combination Chemotherapy Regimens

6.7. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Endocrine Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Selective Estrogen Receptor Modulators (SERMs)

Aromatase Inhibitors

Estrogen Receptor Antagonists

Estrogen Deprivation Therapy

6.8. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors)

Monoclonal Antibodies for Immune Modulation

Cancer Vaccines

6.9. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Radiation Therapy

Stem Cell Therapy

Hyperthermia Treatment

Gene Therapy

Surgical Interventions (Mastectomy, Breast Conserving Surgery)

7. HER2-Positive Breast Cancer Market Regional And Country Analysis

7.1. Global HER2-Positive Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global HER2-Positive Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific HER2-Positive Breast Cancer Market

8.1. Asia-Pacific HER2-Positive Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China HER2-Positive Breast Cancer Market

9.1. China HER2-Positive Breast Cancer Market Overview

9.2. China HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India HER2-Positive Breast Cancer Market

10.1. India HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan HER2-Positive Breast Cancer Market

11.1. Japan HER2-Positive Breast Cancer Market Overview

11.2. Japan HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia HER2-Positive Breast Cancer Market

12.1. Australia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia HER2-Positive Breast Cancer Market

13.1. Indonesia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea HER2-Positive Breast Cancer Market

14.1. South Korea HER2-Positive Breast Cancer Market Overview

14.2. South Korea HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe HER2-Positive Breast Cancer Market

15.1. Western Europe HER2-Positive Breast Cancer Market Overview

15.2. Western Europe HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK HER2-Positive Breast Cancer Market

16.1. UK HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany HER2-Positive Breast Cancer Market

17.1. Germany HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France HER2-Positive Breast Cancer Market

18.1. France HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy HER2-Positive Breast Cancer Market

19.1. Italy HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain HER2-Positive Breast Cancer Market

20.1. Spain HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe HER2-Positive Breast Cancer Market

21.1. Eastern Europe HER2-Positive Breast Cancer Market Overview

21.2. Eastern Europe HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia HER2-Positive Breast Cancer Market

22.1. Russia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America HER2-Positive Breast Cancer Market

23.1. North America HER2-Positive Breast Cancer Market Overview

23.2. North America HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA HER2-Positive Breast Cancer Market

24.1. USA HER2-Positive Breast Cancer Market Overview

24.2. USA HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada HER2-Positive Breast Cancer Market

25.1. Canada HER2-Positive Breast Cancer Market Overview

25.2. Canada HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America HER2-Positive Breast Cancer Market

26.1. South America HER2-Positive Breast Cancer Market Overview

26.2. South America HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil HER2-Positive Breast Cancer Market

27.1. Brazil HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East HER2-Positive Breast Cancer Market

28.1. Middle East HER2-Positive Breast Cancer Market Overview

28.2. Middle East HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa HER2-Positive Breast Cancer Market

29.1. Africa HER2-Positive Breast Cancer Market Overview

29.2. Africa HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. HER2-Positive Breast Cancer Market Competitive Landscape And Company Profiles

30.1. HER2-Positive Breast Cancer Market Competitive Landscape

30.2. HER2-Positive Breast Cancer Market Company Profiles

30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. HER2-Positive Breast Cancer Market Other Major And Innovative Companies

31.1. AstraZeneca plc

31.2. Novartis International AG

31.3. GlaxoSmithKline plc

31.4. Eli Lilly and Company

31.5. Amgen Inc.

31.6. Boehringer Ingelheim GmbH

31.7. Daiichi Sankyo Co. Ltd.

31.8. Incyte Corporation

31.9. BioNTech SE

31.10. MacroGenics Inc.

31.11. CStone Pharmaceuticals Co. Ltd.

31.12. Sorrento Therapeutics Inc.

31.13. Syndax Pharmaceuticals Inc.

31.14. Fate Therapeutics Inc.

31.15. Ambrx Biopharma Inc.

32. Global HER2-Positive Breast Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The HER2-Positive Breast Cancer Market

34. Recent Developments In The HER2-Positive Breast Cancer Market

35. HER2-Positive Breast Cancer Market High Potential Countries, Segments and Strategies

35.1 HER2-Positive Breast Cancer Market In 2029 - Countries Offering Most New Opportunities

35.2 HER2-Positive Breast Cancer Market In 2029 - Segments Offering Most New Opportunities

35.3 HER2-Positive Breast Cancer Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global HER2-Positive Breast Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Endocrine Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global HER2-Positive Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global HER2-Positive Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Johnson & Johnson Services Inc. Financial Performance

Table 81: F. Hoffmann-La Roche AG Financial Performance

Table 82: Merck & Co. Inc. Financial Performance

Table 83: Bayer AG Financial Performance

Table 84: Sanofi S.A. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global HER2-Positive Breast Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Endocrine Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global HER2-Positive Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global HER2-Positive Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Johnson & Johnson Services Inc. Financial Performance

Figure 81: F. Hoffmann-La Roche AG Financial Performance

Figure 82: Merck & Co. Inc. Financial Performance

Figure 83: Bayer AG Financial Performance

Figure 84: Sanofi S.A. Financial Performance

Global Hospital-Acquired Infection Control Market 2022 – Market Opportunities And Strategies

What Is The Healthcare IT Consulting Market Overview In 2022?

How Will The Stem Cell Assay Market Grow In 2022?

Latest Single Use Bioprocessing Market Growth Study 2022-2026 By The Business Research Company

The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the rcm market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the medical tourism market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the clinical chemistry market market research report 2022 with industry size, share, segments and market growth

Breast Cancer Drugs Global Market Report 2025 – By Type (Metastatic Breast Cancer, Triple Negative Breast Cancer, Others (Ductal Carcinoma Insitu, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, Breast Cancer During Pregnancy, Others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels), By End User (Ambulatory, Hospitals, Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Breast Cancer Diagnostics Global Market Report 2025 – By Type (Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types), By Technology (Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies), By Cancer Type (BRCA Breast Cancer, ER & PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Other Cancer Types), By Diagnostic Type (Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies), By End Users (Hospitals and Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Breast Imaging Devices Global Market Report 2025 – By Product Type (Tomosynthesis, Breast Ultrasound, Breast Magnetic Resonance Imaging (MRI), Mammography, Nuclear Imaging, Other Product Types), By Technology (Ionizing, Non Ionizing), By End User (Hospitals and Clinics, Breast Care Centers, Diagnostic Imaging Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Breast Cancer Monoclonal Antibodies Global Market Report 2025 – By Product (Naked Mabs, Conjugated Mabs), By Treatment (Chemotherapy, Surgery & Radiation Therapy, Targeted Therapy, Biologic Therapy, Hormone Therapy), By End-User (Hospitals, Retail Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Breast Implants Global Market Report 2025 – By Type (Silicone Implant, Form-stable Implant, Saline Implant, Structured Saline Implant), By Procedure (Breast Augmentation, Breast Reconstruction), By End User (Hospital, Cosmetology Clinic, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Breast Pumps Global Market Report 2025 – By Product (Open System Breast Pump, Closed System Breast Pump), By Technology (Manual Breast Pump, Battery Powered Breast Pump, Electric Breast Pump), By Application (Personal Use, Hospital Grade) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Breast Imaging Technologies Global Market Report 2025 – By Imaging Technique (Mammography, Breast Ultrasound, Breast MRI, Image Guided Breast Biopsy, Positron Emission Tomography, Other Imaging Techniques), By Technology (Ionizing Breast Imaging Technology, Non Ionizing Breast Imaging Technology), By End User (Hospital, Diagnostic Imaging Centre, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Breast Imaging Devices Market 2022 - By Procedure Type (Tomosynthesis, Breast Ultrasound, Breast MRI, Mammography, Nuclear Imaging), By Technology (Ionizing, Non-Ionizing), By End-User (Hospitals And Clinics, Breast Care Centers, Diagnostic Imaging Centers), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Frequently Asked Questions

What is the definition of the HER2-Positive Breast Cancer market?

How will the HER2-Positive Breast Cancer market drivers and restraints affect the market dynamics? What forces will shape the HER2-Positive Breast Cancer industry going forward?

The HER2-Positive Breast Cancer market major growth driver - Impact Of Immunotherapy Adoption On The HER2-Positive Breast Cancer Market. For further insights on the HER2-Positive Breast Cancer market, request a sample here

What is the forecast market size or the forecast market value of the HER2-Positive Breast Cancer market?

The HER2-Positive Breast Cancer market size has grown strongly in recent years. The HER2-positive breast cancer market size has grown strongly in recent years. It will grow from $10.21 billion in 2024 to $10.96 billion in 2025 at a compound annual growth rate (CAGR) of 7.34%. The growth in the historic period can be attributed to increasing early detection and diagnosis, rising awareness of HER2-positive subtypes, growing investments in research and development, rising adoption of precision medicine, and growing focus on improving patient outcomes. The HER2-positive breast cancer market size is expected to see strong growth in the next few years. It will grow to $14.41 billion in 2029 at a compound annual growth rate (CAGR) of 7.08%. The growth in the forecast period can be attributed to rising demand for liquid biopsy for non-invasive monitoring, rising adoption of combination treatments, growing focus on immunotherapies and novel drug formulations, increasing use of liquid biopsy techniques for non-invasive monitoring, and increasing number of specialized cancer treatment centers. Major trends in the forecast period include advancements in targeted therapies, novel formulations, innovations in immunotherapy approaches, the development of novel HER2-targeted therapies, and advancements in biomarkers for better patient stratification. For further insights on the HER2-Positive Breast Cancer market, request a sample here

How is the HER2-Positive Breast Cancer market segmented?

The HER2-positive breast cancer market covered in this report is segmented –
1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types
2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User Subsegments:
1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors
2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens
3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy
4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation, Cancer Vaccines
5) By Other Treatment Types: Radiation Therapy, Stem Cell Therapy, Hyperthermia Treatment, Gene Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery) For further insights on the HER2-Positive Breast Cancer market, request a sample here

Which region has the largest share of the HER2-Positive Breast Cancer market? What are the other regions covered in the report?

Who are the major players in the HER2-Positive Breast Cancer market?

What are the key trends in the HER2-Positive Breast Cancer market?

Major trends in the HER2-Positive Breast Cancer market include Innovative Therapies In The HER2-Positive Breast Cancer Market. For further insights on the HER2-Positive Breast Cancer market, request a sample here.

What are the major opportunities in the HER2-Positive Breast Cancer market? What are the strategies for the HER2-Positive Breast Cancer market?

For detailed insights on the major opportunities and strategies in the HER2-Positive Breast Cancer market, request a sample here.

How does the HER2-Positive Breast Cancer market relate to the overall economy and other similar markets?

For detailed insights on HER2-Positive Breast Cancer's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the HER2-Positive Breast Cancer industry?

For detailed insights on the mergers and acquisitions in the HER2-Positive Breast Cancer industry, request a sample here.

What are the key dynamics influencing the HER2-Positive Breast Cancer market growth? SWOT analysis of the HER2-Positive Breast Cancer market.

For detailed insights on the key dynamics influencing the HER2-Positive Breast Cancer market growth and SWOT analysis of the HER2-Positive Breast Cancer industry, request a sample here.